<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00664573</url>
  </required_header>
  <id_info>
    <org_study_id>104RA204</org_study_id>
    <secondary_id>2007-000733-19</secondary_id>
    <nct_id>NCT00664573</nct_id>
  </id_info>
  <brief_title>104RA204 Assessment of the Safety and Efficacy of BG9924 in Rheumatoid Arthritis (RA) Participants</brief_title>
  <acronym>RESPOND-EXT</acronym>
  <official_title>Assessment of Safety and Efficacy of BG9924 in Subjects With RA Who Have Participated in Study 104RA202.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biogen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biogen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To observe the long-term treatment with BG9924 when administered to participants with RA who
      previously participated in a Biogen Idec Study.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Analysis of data from 104RA202 failed to meet primary endpoint
  </why_stopped>
  <start_date>November 2007</start_date>
  <completion_date type="Actual">October 2008</completion_date>
  <primary_completion_date type="Actual">October 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To Observe The Long-Term treatment with BG9924 When Administered to Participants with RA who Previously Participated in a Biogen Idec Study</measure>
    <time_frame>Duration of this study is 18 months</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">339</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: BG9924 - dose administered as per Biogen-Idec protocol</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: BG9924 - dose administered as per Biogen-Idec protocol</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: BG9924 - dose administered as per Biogen-Idec protocol</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: BG9924 - dose administered as per Biogen-Idec protocol</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Baminercept alfa (BG9924)</intervention_name>
    <description>dosage administered as per Biogen-Idec protocol</description>
    <arm_group_label>Group 4</arm_group_label>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
    <other_name>BG9924</other_name>
    <other_name>Baminercept alfa</other_name>
    <other_name>LT beta</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Must be a participant from Study 104RA202 (NCT 00664716)

          -  Stable dose of Methotrexate for the duration of the study

        Exclusion Criteria:

          -  Participants with a significant change in their medical history from their previous
             BG9924 study

          -  Any clinically significant infectious illness or serious local infection

        NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Biogen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Coordinating Research Site</name>
      <address>
        <city>Tucuman</city>
        <zip>T4000AXL</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Coordinating Research Site</name>
      <address>
        <city>Sao Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Coordinating Research Site</name>
      <address>
        <city>Budapest</city>
        <zip>H-1036</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Coordinating Research Site</name>
      <address>
        <city>Cuernavaca</city>
        <zip>62270</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Coordinating Research Site</name>
      <address>
        <city>Torun</city>
        <zip>87-100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Coordinating Research Site</name>
      <address>
        <city>Braila</city>
        <zip>810112</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Coordinating Research Site</name>
      <address>
        <city>Moscow</city>
        <zip>127644</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Coordinating Research Site</name>
      <address>
        <city>Leeds</city>
        <state>Yorkshire</state>
        <zip>LS74SA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Brazil</country>
    <country>Hungary</country>
    <country>Mexico</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>December 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 21, 2008</study_first_submitted>
  <study_first_submitted_qc>April 22, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 23, 2008</study_first_posted>
  <disposition_first_submitted>December 17, 2015</disposition_first_submitted>
  <disposition_first_submitted_qc>December 17, 2015</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">January 21, 2016</disposition_first_posted>
  <last_update_submitted>December 17, 2015</last_update_submitted>
  <last_update_submitted_qc>December 17, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 21, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Safety</keyword>
  <keyword>Rheumatoid Arthritis</keyword>
  <keyword>Baminercept alfa</keyword>
  <keyword>Methotrexate</keyword>
  <keyword>BG9924</keyword>
  <keyword>Efficacy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

